Digoxin is a widely used compound for ventricular rate control in patients with atrial fibrillation (AF), despite a scarcity of randomised trial data.Digoxin treatment was associated with a significant increase in all-cause mortality, vascular death, and sudden death in patients with AF. This association was independent of other measured prognostic factors, and although residual confounding could account for these results, these data show the possibility of digoxin having these effects. A randomised trial of digoxin in treatment of AF patients with and without heart failure is needed.
|Cell lines||A549 cells|
|Preparation method||Cells were treated with various concentrations of digoxin for 24 h and seeded in transwell chambers (8-μm pore size, 6.5-mm diameter), which were or were not coated with Matrigel. The upper wells were filled with serum-free media and A549 cells (2×104 or 1×104 cells per well). The lower wells of the transwells contained the same media with 10% FBS and digoxin at various concentrations.|
|Incubation time||24 h|
|Animal models||Sprague Dawley Rats|
|Formulation||0.5% sodium carboxymethylcellulose|
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
Digoxin use and risk of mortality in hypertensive patients with atrial fibrillation.
Okin PM, et al. J Hypertens. 2015 Mar 19. PMID: 25799208.
Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF).
Washam JB, et al. Lancet. 2015 Mar 5. PMID: 25749644.
Humanized vascular endothelial growth factor (VEGF) antibody (bevacizumab; Avastin) is a highly effective monoclonal antibody against metastatic colorectal cancer and several other advanced late stage cancers.
MCC950 is a potent, selective NLRP3 inhibitor with IC50 of 7.5 nM and 8.1 nM in BMDMs and HMDMs, respectively.
MAK683, an epigenetic drug for nasopharyngeal carcinoma, which is more prevalent in China than elsewhere, has entered Phase I clinical trials.
MTX-211 is a enamide hydrate.
GSK369796 shows antimalerial activity with IC50 values of 11.2 nM for 3D7 strain, 12.6 nM for HB3 strain, 17.6 nM for K1 strain.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.